MK-8776 (SCH 900776)

目录号:S2735

MK-8776 (SCH 900776) Chemical Structure

Molecular Weight(MW): 376.25

MK-8776 (SCH 900776)是一种选择性Chk1抑制剂,无细胞试验中IC50为3 nM,比作用于Chk2选择性高500倍。Phase 2。

规格 价格 库存 购买数量  
RMB 1733.35 现货
RMB 3015.42 现货
RMB 7966.05 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的4个实验数据:

  • MCF7 cells were seeded in 60 mm dishes and were pretreated with the specified inhibitor 1 h before stimulation with either vehicle or doxorubicin. Twenty-four hours after treatment, cells were collected and immunoblotted for nSMase2 and actin.

    Cell Death Dis, 2015, 6:e1947.. MK-8776 (SCH 900776) purchased from Selleck.

    (A, B) In the three TNBC cell lines, the numbers of autophagy-related spots were significantly increased in IR-alone group, and this effect was significantly suppressed by MK-8776 (IR vs MK-8776+IR: 65±23 vs 13±8, P<0.0001 in MDA-MB-231; 57±32 vs 18±7, P=0.0014 in BT-549; 43±35 vs 14±10, P=0.021 in CAL-51).

    Acta Pharmacol Sin, 2017, 38(4):513-523. MK-8776 (SCH 900776) purchased from Selleck.

  • HT29 cells were treated with 1 μM V411, 3 μM LY2603618 (LY), 3 μM MK-8776 (MK), 3 μM GNE-900 (GNE) or 0.3 μM ARRY-1A (ARRY) for 24 h. The fraction of γH2AX, pRPA32 (S4/S8), pChk1 (S317) or pChk2 (T68) positive nuclei were determined by single cell immunofluorescent imaging (n=4, mean ± SD). B. HT29 cells were treated as above for 2 or 24 h. Cell lysates were probed with the indicated antibodies by immunoblotting.

    Oncotarget, 2016, 7(51):85033-85048. MK-8776 (SCH 900776) purchased from Selleck.

    Hela cell was trypsinized and plated at 30% confluence in DMEM. 16 hours later, MK-8776 (SCH900776) was added at final concentrations of 0, 5, 10 and 25uM. Another 24 hours later, cells were harvested in RIPA with protease and phosphatase inhibitor cocktail. Total protein concentration was measured by BCA method. Lysates equivalent to 20ug total protein were subject to Western Blot, using total- CHK1, pS345-CHK1 and beta-actin (internal control) antibodies.

    MK-8776 (SCH 900776) purchased from Selleck.

产品安全说明书

Chk抑制剂选择性比较

生物活性

产品描述 MK-8776 (SCH 900776)是一种选择性Chk1抑制剂,无细胞试验中IC50为3 nM,比作用于Chk2选择性高500倍。Phase 2。
靶点
Chk1 [1]
(Cell-free assay)
CDK2 [1]
(Cell-free assay)
3 nM 0.16 μM
体外研究

SCH 900776是Chk2和CDK2的低效抑制剂,IC50分别为1.5 μM 和 0.16 μM。SCH 900776对细胞色素P450人肝微粒体亚型1A2,2C9,2C19,2D6,和3A4没有显著的抑制作用。羟基脲下暴露24小时后,SCH 900776诱导DNA复制能力剂量依赖性损失。SCH 900776增强γ-H2AX对羟基脲,5-氟尿嘧啶,和阿糖孢苷的响应。与抗代谢物结合,SCH 900776在2小时内诱导γ-H2AX的累积,表明复制叉瓦解,并且双链DNA断裂。此外,SCH 900776以剂量依赖的方式抑制Chk1 pS296自磷酸化的积累。增殖的WS1细胞暴露于SCH 900776,与Chk1 pS345快速的,剂量依赖性聚集相关,表明正常细胞的循环群诱导Chk1 pS345在暴露于SCH 900776后,是一部分无效循环,这也许通过AT-家族激酶和DNA-PK驱动。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
U251 M4XkUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzx[lNJOjByL{KwNFAhdk1? NVrFOFVLOjRiaB?= NFG0e4Jl\WO{ZXHz[ZMhfGinIFnDOVAhd2ZiR3XtZ4l1[WKrbnW= NVruXZdEOjR|NUm1NlY>
HCT115 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIr1PVczODBxMkCwNEBvVQ>? Mlm0NlQhcA>? MkLo[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n NVPlTHp1OjR|NUm1NlY>
SW620 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPkNlAxNzJyMECgcm0> MmDiNlQhcA>? M2\JWoRm[3KnYYPld{B1cGViSVO1NEBw\iCJZX3jbZRi[mmwZR?= NILnNJEzPDN3OUWyOi=>
IGROV-1 MlOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWqyNFAwOjByMDDuUS=> NYn1XlJWOjRiaB?= NFGwXmtl\WO{ZXHz[ZMhfGinIFnDOVAhd2ZiR3XtZ4l1[WKrbnW= NIL6Z5YzPDN3OUWyOi=>
HCT116 M4HZNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\BW2IzODBxMkCwNEBvVQ>? NVXTNoZkOjRiaB?= NF7pVYdl\WO{ZXHz[ZMhfGinIFnDOVAhd2ZiR3XtZ4l1[WKrbnW= MlfhNlQ{PTl3Mk[=
MCF10A NWrtN5ZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\0clIxOC9{MECwJI5O Mn7uNlQhcA>? NWDCTGtO\GWlcnXhd4V{KHSqZTDJR|UxKG:oIFflcYNqfGGkaX7l MlnMNlQ{PTl3Mk[=
MiaPaCa-2 NF3XUXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjoN3AzODBxMkCwNEBvVQ>? M3;hdlI1KGh? M1TMd4Rm[3KnYYPld{B1cGViSVO1NEBw\iCJZX3jbZRi[mmwZR?= M{PzfVI1OzV7NUK2
MDA-MB-231 NEOweHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVeyNFAwOjByMDDuUS=> NFzvVHIzPCCq NI[4N29l\WO{ZXHz[ZMhfGinIFnDOVAhd2ZiR3XtZ4l1[WKrbnW= M1TFblI1OzV7NUK2
HCC2998 NHfnfpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILnZlEzODBxMkCwNEBvVQ>? MXOyOEBp MlnE[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n NHXxXYwzPDN3OUWyOi=>
U87 MlTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLhWmpROjByL{KwNFAhdk1? NGjiZ2ozPCCq NWHReZBr\GWlcnXhd4V{KHSqZTDJR|UxKG:oIFflcYNqfGGkaX7l MXWyOFM2QTV{Nh?=
MDA-MB-435 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rORlIxOC9{MECwJI5O M{HhfFI1KGh? M3;sT4Rm[3KnYYPld{B1cGViSVO1NEBw\iCJZX3jbZRi[mmwZR?= MW[yOFM2QTV{Nh?=
SNB19 NIi1[3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfjZpJnOjByL{KwNFAhdk1? M3\pTVI1KGh? NYHCVnBx\GWlcnXhd4V{KHSqZTDJR|UxKG:oIFflcYNqfGGkaX7l NH76TFYzPDN3OUWyOi=>
U20S NWLLWpNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DSW|IxOC9{MECwJI5O M{K3blI1KGh? NVLJOWo3\GWlcnXhd4V{KHSqZTDJR|UxKG:oIFflcYNqfGGkaX7l M4fEU|I1OzV7NUK2
A498 MmD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXThR2l2OjByL{KwNFAhdk1? NHrqZnMzPCCq Ml3X[IVkemWjc3XzJJRp\SCLQ{WwJI9nKEenbXPpeIFjcW6n NXK0UWp6OjR|NUm1NlY>
TK10 Ml[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jCO|IxOC9{MECwJI5O NFnnT3EzPCCq NYfBNVBJ\GWlcnXhd4V{KHSqZTDJR|UxKG:oIFflcYNqfGGkaX7l M{TN[FI1OzV7NUK2
AsPC-1 M4\nZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFj3TYgzODBxMkCwNEBvVQ>? NILhcYYzPCCq M{jKN4Rm[3KnYYPld{B1cGViSVO1NEBw\iCJZX3jbZRi[mmwZR?= MVKyOFM2QTV{Nh?=
H23 NYCzeHZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vhdlUxOCCwTR?= MoLkNlQhcA>? MnfwSG1UVw>? M2r5RoVvcGGwY3XzJJRp\SClaHXtc5NmdnOrdHn6ZZRqd25idH:gVG1Z Mkn1NlQyOTN3NEm=
H1437 M3niW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[1NFAhdk1? MYCyOEBp M37VTmROW09? NVzNUopH\W6qYX7j[ZMhfGinIHPo[Y1we2Wwc3n0bZpifGmxbjD0c{BRVVh? NVnXZo51OjRzMUO1OFk>
H1993 MnHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUW1NFAhdk1? MnrSNlQhcA>? MknhSG1UVw>? M17Ib4VvcGGwY3XzJJRp\SClaHXtc5NmdnOrdHn6ZZRqd25idH:gVG1Z MkS0NlQyOTN3NEm=
H1299 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILaUoc2ODBibl2= M331VlI1KGh? NFG1SnZFVVOR NYnhS4l4\W6qYX7j[ZMhfGinIHPo[Y1we2Wwc3n0bZpifGmxbjD0c{BRVVh? M3LOfFI1OTF|NUS5
AsPC-1 M2C2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPCdmxkOTBvMUCwNEBvVQ>? NXPpfm0{OjRvNEjo NWPlfYNy\W6qYX7j[ZMhfGinIHPo[Y1we2Wwc3n0bZpifGmxbjD0c{Bo\W2laYThZolv\Q>? MoXUNlM5ODR2MkK=
MiaPaCa-2 NF3LeFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVqxNE0yODByIH7N M3G2WFI1NTR6aB?= MUnlcohidmOnczD0bIUh[2inbX;z[Y5{cXSrenH0bY9vKHSxIHflcYNqfGGkaX7l MlvnNlM5ODR2MkK=
BxPC-3 MluzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mor1NVAuOTByMDDuUS=> M1fWWlI1NTR6aB?= NVLI[GhZ\W6qYX7j[ZMhfGinIHPo[Y1we2Wwc3n0bZpifGmxbjD0c{Bo\W2laYThZolv\Q>? MWOyN|gxPDR{Mh?=
SKOV3 NWG1ZZF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7HNE4{KML3TR?= MoPzPEBl Mlzsd4Vve2m2aYrld{B1cGViY3XscEBtcW6nczD0c{Bo\W2laYThZolv\cLi Mn;sNlM2PDh{Nkm=
OVCAR-8 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPyN|JIOC5|INM1US=> NGTnUmo5KGR? MmT2d4Vve2m2aYrld{B1cGViY3XscEBtcW6nczD0c{Bo\W2laYThZolv\cLi NGXoPFUzOzV2OEK2PS=>
MV-4-11 MVXBdI9xfG:|aYOgRZN{[Xl? M3LCcVExOC15MECgcm0> MmjVOFghcA>? Mn3ubY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= NGTFdY4zOzV|NkeyNS=>
U937 MXnBdI9xfG:|aYOgRZN{[Xl? NXvKU4pPOTByLUewNEBvVQ>? NG\RRpY1QCCq MkX1bY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= NU\kdoJTOjN3M{[3NlE>
MOLM-13  MVLBdI9xfG:|aYOgRZN{[Xl? NGqzXXUyODBvN{CwJI5O MVG0PEBp NXnmfXlHcW6mdXPld{BieG:ydH;zbZMh\G:|ZTDk[ZBmdmSnboTsfS=> M1fpd|I{PTN4N{Kx
A2058  M2raTWNmdGxiVnnhZoltcXS7IFHzd4F6 M1r4dFM4NjVvM{CwJI5O NXPZU5dLPzJiaB?= MnXwSG1UVw>? M{DaXpJm\HWlZYOgeIhmKE2NLUG3O|UhTUN3MNMgZpkhPS2ob3zkJJRwKGGwIHH2[ZJi\2Vib3[gOFUhdk1? NEXDV4QzOzF2OE[4OC=>
H2009 M1fYW2NmdGxiVnnhZoltcXS7IFHzd4F6 NWXGd|J[PTByIH7N M1rRNlczKGh? NFLMeolFVVOR M1H2VZJme3WudIOgbY4hTzFxUz3wbIF{\SCjY3P1cZVt[XSrb36gZ49u[mmwZXSge4l1cCCPSz2xO|c2 NWD3O4c3OjNzNEi2PFQ>
Su.86.86 NEmwXWFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NW\Vb4N[PTByIH7N NFvvbY84OiCq MmDoSG1UVw>? MlvadoV{fWy2czDpckBIOS:VLYDoZZNmKGGlY4XteYxifGmxbjDjc41jcW6nZDD3bZRpKE2NLUG3O|U> NYLyXI41OjNzNEi2PFQ>
HRE NXXEdYdDS2WubDDWbYFjcWyrdImgRZN{[Xl? MYO1NFAhdk1? MY[3NkBp NEX4T|BFVVOR M{TwfpJme3WudIOgbY4hTzFxUz3wbIF{\SCjY3P1cZVt[XSrb36gZ49u[mmwZXSge4l1cCCPSz2xO|c2 NWTUWGRUOjNzNEi2PFQ>
HMEC MlnYR4VtdCCYaXHibYxqfHliQYPzZZk> NFvmeZk2ODBibl2= NFjGSmY4OiCq MXPEUXNQ NFWwV3Jz\XO3bITzJIlvKEdzL2OtdIhie2ViYXPjeY12dGG2aX;uJINwdWKrbnXkJJdqfGhiTVutNVc4PQ>? MlTRNlMyPDh4OES=
U2OS  NHHWfndHfW6ldHnvckBCe3OjeR?= MmTsNkDDvU1? M{e3PFAuOjRiaB?= NWn5N5dZcW6mdXPld{BxcG:|cHjvdplt[XSrb36gc4YhS2itMTDheEB{\XKrbnWgN|Q2KGG2IHLveIgh[2:wY3XueJJifGmxboOgZZMh\WG{bImgZZMhOiCqIHHmeIVzKGGmbXnubZN1emG2aX;u NUfWeGFpOjJ7M{exOFc>
U2OS  NFm5VGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7ONE0yOCEEtV2= MYGyOE81QCCq MX3pcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 M3HVelIzQTN5MUS3
U937 MknwSpVv[3Srb36gRZN{[Xl? MXmxNFAuPTByIH7N NVPTOlJGPCCqwrC= M1LwOYRm[3KnYYPld{B1cGViY4n0ZZJi[mmwZT3pcoR2[2WmIFPob|Eh[XW2b4Doc5NxcG:{eXzheIlwdiCjdDDT[ZIzQTcEoHHu[EBxemW4ZX70d{BE\GN{NVGg[I94dnKnZ4XsZZRqd25? Mo\GNlI5Pjl6Nkm=
U937 M1;WcGZ2dmO2aX;uJGF{e2G7 MVuxNFAhdk1? MnHLOEBpyqB? NGjSe2tz\X[ncoPld{B1cGViY4n0ZZJi[mmwZT3pcoR2[2WmIHnubIljcXSrb36gc4bDqDOKLYTofY1q\GmwZTDpcoNwenCxcnH0bY9vKGmwdH:gSG5C Mnn0NlI5Pjl6Nkm=
U937 M3jB[WZ2dmO2aX;uJGF{e2G7 NWXkOY1[OTByLUWwNEBvVQ>? NUO2dlhUPCCqwrC= NUDNOmJXcW6mdXPld{BqdmO{ZXHz[YQheGixc4Doc5J6dGG2aX;uJI9nKEh{QWi= NFXGRW8zOjh4OUi2PS=>
HL-60 MWTBdI9xfG:|aYOgRZN{[Xl? NVPPdpJ[OzBxMUCwM|MxOCCwTR?= MoDuNlQhcA>? Mm\PSG1UVw>? MkHF[Y5p[W6lZYOgZ5l1[XKjYnnu[U1qdmS3Y3XkJIFxd3C2b4Ppdy=> M3r2WlIzQDZ7OE[5
ML-1 Mme1RZBweHSxc3nzJGF{e2G7 MofWNlUwPTBxMUCwJI5O NYXQR49ROjRiaB?= NEi3eWpFVVOR NHTqbFVmdmijbnPld{BkgXSjcnHibY5mNWmwZIXj[YQh[XCxcITvd4l{ MUOyNlg3QTh4OR?=
HCT116 MojFSpVv[3Srb36gRZN{[Xl? MUGxJOK2VQ>? M2O0UFI1KGh? M2WyPIFjem:pYYTld{Bw\iClZXzsJIN6[2ynIHHydoV{fMLi MlT5NlI2OTB3NkC=
U2OS NX;penRVTnWwY4Tpc44hSXO|YYm= NYjuOIFTOSEEtV2= NFOyN|gzPCCq NUTn[nR1[WK{b3fheIV{KG:oIHPlcIwh[3mlbHWgZZJz\XO2wrC= Mo\RNlI2OTB3NkC=

... Click to View More Cell Line Experimental Data

体内研究 相对于gemcitabine或SCH 900776单独给药,Gemcitabine给药30分钟后,4 mg/kg SCH 900776足以诱导γ-H2AX生物标志物,而8 mg/kg增强肿瘤药效动力学和退化响应。递增剂量的SCH 900776 (16 mg/kg和32 mg/kg)诱导肿瘤响应持续改进。重要的是,在BALB/c 小鼠体内,SCH 900776的剂量与强的生物标志物活化相关,而提高的肿瘤响应与gemcitabine对血液学指标增强的毒性无关。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

动物实验:[1]
+ 展开
  • Animal Models: 皮下注射A2780 或 MiaPaCa2细胞的额雌性裸鼠
  • Formulation: 在 20% 羟丙基β-环糊精中形成
  • Dosages: ~50 mg/kg
  • Administration: 腹腔内注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 3 mg/mL (7.97 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用:
4% DMSO+30% propylene glycol
5 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 376.25
化学式

C15H18BrN7

CAS号 891494-63-6
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01870596 Completed Adult Acute Megakaryoblastic Leukemia|Adult Acute Monoblastic Leukemia|Adult Acute Monocytic Leukemia|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With Maturation|Adult Acute Myeloid Leukemia With Minimal Differentiation|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL|Adult Acute Myeloid Leukemia Without Maturation|Adult Acute Myelomonocytic Leukemia|Adult Erythroleukemia|Adult Pure Erythroid Leukemia|Alkylating Agent-Related Acute Myeloid Leukemia|Recurrent Adult Acute Myeloid Leukemia National Cancer Institute (NCI) May 2013 Phase 2
NCT00907517 Terminated Myelogenous Leukemia, Acute|Leukemia, Lymphocytic, Acute|Leukemia, Lymphoblastic, Acute, Philadelphia-Positive|Myelogenous Leukemia, Chronic, Aggressive Phase Merck Sharp & Dohme Corp. July 2009 Phase 1
NCT00779584 Completed Hodgkin Disease|Lymphoma, Non-Hodgkin|Neoplasms Merck Sharp & Dohme Corp. October 2008 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I would like to know whether your product S2735 is the optically pure R enantiomer or whether it is a racemic mix.

  • 回答:

    Our S2735 MK-8776 (SCH 900776) is R enantiomer.

Chk Signaling Pathway Map

Chk Inhibitors with Unique Features

相关Chk产品

Tags: 购买MK-8776 (SCH 900776) | MK-8776 (SCH 900776)供应商 | 采购MK-8776 (SCH 900776) | MK-8776 (SCH 900776)价格 | MK-8776 (SCH 900776)生产 | 订购MK-8776 (SCH 900776) | MK-8776 (SCH 900776)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID